Bui Mai Thao, Fernández-Eulate Gorka, Evangelista Teresinha, Lacène Emmanuelle, Brochier Guy, Labasse Clémence, Madelaine Angéline, Chanut Anaïs, Beuvin Maud, Borsato-Levy Favienne, Biancalana Valérie, Barcia Giulia, De Lonlay Pascale, Laporte Jocelyn, Böhm Johann, Romero Norma Beatriz
Institute of Myology, Neuromuscular Morphology Unit, Sorbonne Université, INSERM, GHU Pitié-Salpêtrière, Paris, France.
Institute of Myology, Neuromuscular Diseases Reference Center Nord/Est/Ile-de-France, GHU Pitié-Salpêtrière, APHP, Paris, France.
Acta Neuropathol Commun. 2024 Dec 20;12(1):191. doi: 10.1186/s40478-024-01882-0.
Neuromuscular disorders (NMD) with neonatal or early infantile onset are usually severe and differ in symptoms, complications, and treatment options. The establishment of a diagnosis relies on the combination of clinical examination, morphological analyses of muscle biopsies, and genetic investigations. Here, we re-evaluated and classified a unique collection of 535 muscle biopsies from NMD infants aged 0-6 months examined over a period of 52 years. We aimed to assess the importance and contribution of morphological muscle biopsy analyses for the establishment of a precise and accurate molecular diagnosis. Altogether, 82% of the biopsies showed typical structural myofiber anomalies highly suggestive of specific NMD classes (congenital myopathies, metabolic myopathies, lower motor neuron (LMN) and neuromuscular junction (NMJ) disorders, muscular dystrophies, inflammatory myopathies), while the remaining 18% showed no or only non-specific histological abnormalities. The diagnostic success rate differed among the NMD classes and was particularly high for congenital myopathies as illustrated by the identification of causative genes in 61% of cases. This is essentially due to the presence of characteristic histopathological hallmarks on biopsies visible by light or electron microscopy often pointing to specific genes. In contrast, metabolic myopathies commonly displayed non-specific features on muscle sections, led to the identification of causative genes in only 19% of the patients, and typically required additional enzymatic tests to establish a more precise diagnosis. The evolution of sequencing technologies fundamentally improved molecular diagnosis and also shifted the relevance of muscle biopsies within the diagnostic process. Depending on the clinical presentation of the patients, direct gene or panel sequencing may be the preferred method nowadays. However, histological and ultrastructural examinations of muscle sections are still frequently useful and can constitute an elemental step in the diagnostic process-either by directing purposeful gene sequencing or pointing to genes and pathogenic variants identified by next-generation sequencing (NGS), or by complementing clinical findings and biochemical analysis methods.
新生儿期或婴儿早期发病的神经肌肉疾病(NMD)通常病情严重,在症状、并发症和治疗选择方面存在差异。诊断的确立依赖于临床检查、肌肉活检的形态学分析以及基因检测三者的结合。在此,我们对在52年期间检查的535例0至6个月大的NMD婴儿的独特肌肉活检样本进行了重新评估和分类。我们旨在评估形态学肌肉活检分析对于确立精确准确的分子诊断的重要性和贡献。总体而言,82%的活检样本显示出典型的结构肌纤维异常,强烈提示特定的NMD类别(先天性肌病、代谢性肌病、下运动神经元(LMN)和神经肌肉接头(NMJ)疾病、肌营养不良症、炎性肌病),而其余18%的样本未显示或仅显示非特异性组织学异常。诊断成功率在不同的NMD类别中有所不同,对于先天性肌病尤其高,例如在61%的病例中鉴定出致病基因。这主要是由于活检样本上存在特征性的组织病理学特征,通过光学或电子显微镜可见,常常指向特定基因。相比之下,代谢性肌病在肌肉切片上通常表现为非特异性特征,仅在19%的患者中鉴定出致病基因,并且通常需要额外的酶学检测来确立更精确的诊断。测序技术的发展从根本上改善了分子诊断,也改变了肌肉活检在诊断过程中的相关性。根据患者的临床表现,如今直接基因测序或基因panel测序可能是首选方法。然而,肌肉切片的组织学和超微结构检查仍然常常有用,并且可以构成诊断过程中的一个基本步骤——要么通过指导有针对性的基因测序,要么指向通过下一代测序(NGS)鉴定的基因和致病变异,要么通过补充临床发现和生化分析方法。